Biocon, Ltd.
http://www.biocon.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Biocon, Ltd.
Pharma Readies For Price Caps On Glargine, Teneligliptin, Lenalidomide In India
India’s national list of essential medicines 2022 features 34 additions, including insulin glargine, teneligliptin, lenalidomide, bedaquiline and montelukast, with price control expected to follow on these drugs.
Pharma Readies For Price Caps On Glargine, Teneligliptin, Lenalidomide In India
India’s national list of essential medicines 2022 features 34 additions, including insulin glargine, teneligliptin, lenalidomide, bedaquiline and montelukast, with price control expected to follow on these drugs.
Equillium Buys Metacrine For Its Cash, Will Outsource Lead Drug Candidate
Deal Snapshot: Equillium will gain $33m, extending its cash runway into 2024 and past several upcoming milestones, but it will seek a strategic partner for Metacrine’s stalled FXR agonist MET642.
Biocon Gets FDA Observations At Key Biosimilars Facilities
Biocon has revealed that an FDA inspection of key biosimilars manufacturing facilities in Bengaluru and Malaysia in August has resulted in numerous Form 483 observations across three Biocon Biologics sites.
Company Information
- Industry
- Biotechnology
- Distributors
- Medical Devices
- Pharmaceuticals
- Services
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Biocon Sdn Bhd.
- Biocon Limited
- Biocon Biologics India Ltd
- Bicara Therapeutics